NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

Tucson, AZ, July 29, 2021 --( NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.

Click here to read more

Recent Posts

See All